Good morning :)
$
₹
Anavex Life Sciences Corp

Anavex Life Sciences Corp

AVXL

NASDAQ
Asset Logo

Anavex Life Sciences Corp

AVXL

NASDAQ
$1.254.58% (+0.05)
$
₹
$1.254.58% (+0.05)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $105.7M the stock is ranked 4631

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.97
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.14
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Price Upside

+1566.67%

Earnings Growth

+38.89%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 1566.67% growth, versus a trailing 3-year CAGR of -41.29%.

2026
Current$1.2Baseline
Analyst Target - 1 year
Target$20+1566.67%

All values in $

202220232024202520262027$6.31$11.54$16.77Target+1566.67%
2026
Current$1.2Baseline
Analyst Target - 1 year
Target$20+1566.67%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-0.54Baseline
Forecast for Sep 2026
High$-0.33+38.89%
Average$-0.33+38.89%
Low$-0.33+38.89%

All values in $

202120222023202420252026-0.53-0.62-0.6-0.52-0.54Low+38.89%Average+38.89%High+38.89%
2025
Current$-0.54Baseline
Forecast for Sep 2026
High$-0.33+38.89%
Average$-0.33+38.89%
Low$-0.33+38.89%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-9.8
-5.6
-5.3
-3.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000000
Net Income-10.54-12.21-11.62-12.11-11.19-13.24-9.82-5.68-5.33-3.19
Net Profit Margin----------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Anavex Life Sciences Corp -0.970
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare AVXL with any stock or ETF
Compare AVXL with any stock or ETF
Comparing from
AVXL
ABBV
AMGN
Loading...

Frequently asked questions

  1. Anavex Life Sciences Corp (AVXL) share price today is $1.25 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $1.28 and a day low of $1.22.

  2. Anavex Life Sciences Corp stock trades on NASDAQ under the ticker symbol AVXL.

  3. Anavex Life Sciences Corp's market capitalization is $105.67M as of November 5, 2026 at 2:29 AM IST.

  4. Anavex Life Sciences Corp's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Anavex Life Sciences Corp's price-to-book (P/B) ratio is 0.97 as of November 4, 2026.

  6. Yes, You can buy Anavex Life Sciences Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Anavex Life Sciences Corp shares in three steps: 1. Search Anavex Life Sciences Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Anavex Life Sciences Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Anavex Life Sciences Corp (AVXL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 7.9681 shares at the current price of $1.25.

Loading...